IBS has devised a unique method CSSA^TM to generate HIGH-HIT Databases^TM (HH-DBs) focused on specific pharmacological targets. CSSA is based on the application of front-end software and specially designed large databases comprising more than 300,000 commercial and trial bioactive compounds.

This method enables IBS to generate HH-DBs^TM for our clients from synthetic & natural compounds held in stock at InterBioScreen. HH-DBs^TM are orders of magnitude more saturated with compounds of predictable, highly specific bioefect than are random databases.

"Save your time and money: choose a HH-DB
and get Hits in the field of your interest right now."
Sergei Zasedatelev,
Ph.D., Executive Director

HIGH-HIT Databases are available for target areas as follows:

Antivirals	Antibacterials
Tuberculostatics	Anti-infectives
Cancerostatics	Anti-inflammatories
Antidiabetics	Cardiovascular agents
Hypo/hypertensives	CNS regulators

Near completion are focused High-Hit databases for another 10 areas.

IBS has available one of the world's largest collections of Natural Compounds, their derivatives and mimetics (STOCK2003N) comprising upwards of 25 000 compounds.

"Over millions of years of evolution nature has created unique secondary metabolites which as a rule have protective and regulatory functions in biocenosis and are often active in minor and extra minor doses. This is virtually an inexhaustible source of ideas to draw upon in creating new generation pharmaceuticals and new drugs for the next Millennium."
Victor Kartsev,
D.Sc.,Vice President,
Science & International relations

IBS has organized a network of operating international laboratories which employ more than 1500 highly qualified chemists who carry out targeted synthesis of tens of thousands of new chemical drug-like compounds which cannot be synthesized by combinatorial methods:

• Synthesis of new and unusual classes of organic compounds with the aim to radically maximize the diversity of our customers' Libraries
• Synthesis of new, patentable analogs and highly diversified functionalized derivatives of commercial pharmaceuticals and trial pharmaceuticals; synthesis of specially designed targeted subsets for screening
• Synthesis of new derivatives of natural alkaloids, terpenoids, flavonoids, cumarins etc. (under the 1999 Project NC99 it is anticipated to obtain up to 10 000 new compounds on the basis of rare natural matrices)
• Total synthesis of difficult-to-obtain genuine natural compounds
• Directed synthesis of building blocks for Combinatorial Chemistry of Natural products.

"One of our major goals is to make rare natural compounds available for commercial use in present-day medicine and agrochemistry."
Olga Shubina,
Ph.D., Senior Manager, Chemistry